ArticleMacromolecular rapid communications2026
Antimicrobial Cyclic Peptidomimetics.
Article in Macromolecular rapid communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial Cyclic Peptidomimetics.Macromolecular rapid communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antimicrobial resistance is a critical global healthcare issue that urgently needs the development of new antimicrobial agents. Herein, we developed new and discrete cationic amphipathic cyclic peptidomimetics as potential antimicrobial agents to combat multidrug-resistant bacteria. These cyclic oligomers of different alkyl chain lengths are easy to obtain via carbodiimide-mediated condensation reaction and using aza-crown ether as the core reactant. The antimicrobial activity, membrane perturbation effects, and toxicity of the compounds are strongly dependent on the hydrophobic alkyl chain length, as longer lipid chains result in greater antimicrobial potency and membrane disruption but also poorer biocompatibility. For example, cyclic compound bearing 16-carbon chain (CYPEP-C16) has the best bacteriostatic activity against several bacteria strains with minimum inhibitory concentrations of 16 µg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.